RÉSUMÉ
Objective To assess the clinical effectiveness ofWenyang-Gushen-Huayu decoction on treating diabetic nephropathy (DN).Methods One hundred and twenty DN patients in Hospital of Penglai Chinese Medicine were included and randomly divided into treatment group and observation group. Both groups were given conventional treatment, and the treatment group was added withWenyang-Gushen-Huayu decoction. One course of treatment lasted four weeks in both groups and each group was observed for 2 courses. The clinical symptoms, vital signs, urinary albumin excretion rate (UAER), and 24 h urinary proteinwere observed. Results The treatment group showed significantly higher effective rate (93.34%vs.73.33%) than that in the control groupa(χ2=8.640,P=0.003). TheWenyang-Gushen-Huayu decoction significantly improved the symptoms of waist chills (2.47 ± 1.11vs.2.92 ± 1.36,t=1.986), edema of face and feet (1.81 ± 0.96vs.2.14 ± 1.01,t=5.165), fatigue of the gods (2.83 ± 1.12vs.3.51 ± 1.18,t=3.237), UAER (326.4 ± 98.7μg/minvs. 421.5 ± 185.6μg/min;t=3.504) and UP (0.7 ± 0.33 g/24hvs. 1.0 ± 0.37 g/24h;t=1.845).ConclusionsTheWenyang-Gushen-Huayu decoction could improve the symptoms and reduce UAER of DN patients.
RÉSUMÉ
Objective:To investigate the effects of fluvastatin on high-sensitivity c-reactive protein( hs-CRP) , tumor necrosis fac-tor-α(TNF-α), urine albumer excretion rate (UAER)and serum creatinine (Cr) in the patients with early diabetic nephropathy. Methods:Totally 69 patients with early diabetic nephropathy were randomly divided into the observation group with 34 cases and the control group with 35 cases. The observation group was treated by low-protein diet plus fluvastatin, and the control group was treated by low-protein diet only. The course of treatment was 8 weeks. Totally 65 nondiabetic persons were selected as the normal group, and the levels of TNF-α, hs-CRP, UAER, ALT and Cr were detected before and after the treatment. Results:The levels of TNF-α, hs-CRP and UAER in the observation group and the control group were significantly higher than those in the normal group(P0. 05). Compared with that before the treatment, the level of UAER was de-creased significantly in the control group after the treatment (P0. 05). In the observation group, the levels of TNF-α, hs-CRP and UAER were all decreased sig-nificantly after the treatment (P<0. 05). Conclusion:UAER, hs-CRP and TNF-α are closely connected with diabetic nephropathy. Fluvastatin can decrease the levels of TNF-α, hs-CRP and UAER. Low-protein diet plus fluvastatin is effective and safe in the treat-ment of early diabetic nephropathy, and the efficacy is superior to that of low-protein diet only.
RÉSUMÉ
Objective To observe the effect of beraprost sodium on elderly patients with type 2 diabetic nephropathy (DN) and to observe the change of the plasma vascular endothelial growth factor(VEGF) and endothelin(ET-1) level.Methods The levels of plasma VEGF and ET-1 in the 27 cases of type 2 diabetes without nephropathy and 48 cases with type 2 diabetic nephropathy were measured.The possible role of VEGF and ET-1 in diabetic nephropathy was explored.48 cases of type 2 diabetic nephropathy patients were randomly divided into 2 groups:the conventional treatment group and beraprost sodium treatment group.The changes of VEGF and ET-1 level in the 2 groups before and after the treatment were measured.Results The plasma VEGF and ET-1 levels were significantly higher in type 2 diabetic nephropathy patients than in type 2 diabetes patients without nephropathy(P ＜0.01).Compared with the control group,beraprost sodium significantly reduced the plasma VEGF and ET-1 levels in patients with diabetic nephropathy(P ＜ 0.05),and also reduced urinary albumin excretion rates (UAER) significantly (P ＜ 0.05).Conclusions The increasing level of VEGF and ET-1 plays an important role in the onset of diabetic nephropathy.Beraprost sodium can correct the balance of the plasma VEGF and ET-1 in treatment of patients with diabetic nephropathy,improves the endothelial function in diabetic nephropathy,decreases urine protein,and plays a protective role in diabetic nephropathy.
RÉSUMÉ
s:Objective To explore effect of the Tangshen Tongluo (TSTL) recipe on ET and ANP in patients with early diabetic nephropathy (DN). Methods 45 Cases of early DN patients were randomly divided into the TSTL recipe group (25 cases) and Lotensin group (20 cases). After the treatment of TSTL recipe and Lotensin, TCM symptom, the level of FBG, HbA1c, ET, ANP, TC, TG, HDL-C, LDL-C and urine micro albumen excretion rate (UAER) were detected. Results After the treatment of TSTL recipe and Lotensin, TCM symptom, the level of FBG, ET, ANP, TC, TG, LDL-C and UAER were found markedly lower in the TSTL recipe than that in the Lotensin group (P
RÉSUMÉ
Objective To analyse the risk factors relating to diabetic peripheral neuropathy(DPN).Methods 214 type 2 DM cases were investigated and the factors relating to DPN were analysed including age 、diabetic duration 、fasting blood glucose(FBG) 、post blood glucose(PBG)、 HbA_1c、blood pressure(BP)、 urinary albumin excretory rate(UAER)and lipid.Results Logistic regresstion analysis showed that UAER and FBG were relatively independent risk factors.Conclusion In many risk factors UAER and FBG are the most important factors of all in developling DPN.
RÉSUMÉ
Objective To investigate the clinical significance of urine transferrin in the type 2 diabetic nephropathy and primary chronic glomerular disease. Methods The level of TRF and UAER in the urine of 114 patients with type 2 diabetes mellitus (T2DM), 108 patients with CGD and 30 healthy patients was measured by rate nephelometry and analyzed. Results Urine TRF significantly increased earlier than ALB at the early stage of DN; Linear correlation was found by correlation analysis between the level of TRF in urine level and the quantity of protein in urine. Conclusion TRF in urine obviously increased at the early stage of DN. It was more sensitive than UAER to reflect the early renal injury of DM. A statistically significant correlation was found between the TRF level and the quantity of protein in the urine.